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 Introduction 
Methods 
Conclusions 
We hypothesized that myr-gp91ds (2-10 μM) would dose-dependently attenuate 
fMLP induced PMN SO release at lower concentrations compared to tat conjugated 
or tat conjugated gg spacer-gp91ds peptides. Moreover, we also predict that both 
myristic acid and tat conjugated gg spacer gp91ds peptides would significantly 
attenuate fMLP-induced leukocyte SO release compared to native or untreated 
controls without affecting cell viability. 
Unconjugated native sequence did not inhibit the fMLP induced SO response at 
the highest dose tested (80 µM). Myr-peg gp91ds NADPH oxidase peptide 
inhibitor significantly attenuated leukocyte SO release dose dependently 
compared to untreated or native sequence (myr-peg-gp91ds; 5-10 µM). The tat 
conjugated gp91ds inhibitors (both 80 µM) significantly attenuated fMLP-
induced leukocyte SO release, but to a lesser extent than the myr-peg linked 
inhibitor and were not different from native gp91ds. These results suggest that 
myr-peg-gp91ds is more cell permeable and therefore can inhibit fMLP-induced 
SO release from leukocytes at lower doses compared to tat gp91ds. 
Results 
Isolation of PMNs 
Male Sprague-Dawley rats (350–400 g, Charles River), used as PMN donors, were 
anesthetized with 2.5 % isoflurane and given a 16 ml intraperitoneal injection of 
0.5% glycogen (Sigma Chemical) dissolved in PBS. Rats were reanesthetized with 
isoflurane 16–18 h later, and the PMNs were harvested by peritoneal lavage in 30 ml 
of 0.9% NaCl, as previously described (2,5). The peritoneal lavage fluid was 
centrifuged at 200 g for 10 min at 4°C. The PMNs were then washed in 20 ml PBS 
and centrifuged at 200 g for 10 min at 4°C. Thereafter, the PMNs were 
resuspended in 2.5 ml PBS and density was calculated. The PMNs preparation were 
>90% pure and >95% viable according to microscopic analysis and exclusion of 
0.3% trypan blue, respectively.  Cell viability among all study groups was 
determined by 0.3% trypan blue exclusion. 
Measurement of SO Release From Rat PMNs 
The SO release from PMNs was measured spectrophotometrically (model 260 
Gilford, Nova Biotech; El Cajon, CA) by the reduction of ferricytochrome c (2,5). 
The PMNs (5 x106) were resuspended in 450 μl PBS and incubated with 
ferricytochrome c (100 µM, Sigma Chemical) in a total volume of 900 μl PBS in the 
presence or absence of  myristric acid conjugated (2 to 10 μM), tat conjugated (80 
µM) or native gp91ds (80 µM) for 15 min at 37°C in spectrophotometric cells. The 
PMNs were stimulated with 1 μM fMLP (Calbiochem) in a final reaction volume of 
1.0 ml.  Absorbance at 550 nm was measured every 30 sec for  up to 120 sec for 
fMLP and the change in absorbance (SO release) from PMNs was determined 
relative to time 0. 
Cell Viability 
Cell viability was determined by combining 0.5 ml of the samples from 
spectrophotometric analysis using trypan blue exclusion (0.3%).  Then, 20 μl of the 
combined sample was placed on to a hemocytometer, and 100-150 cells were 
subsequently counted using microscopic analysis. 
Statistical Analysis 
All data in the text and figures are presented as means ± S.E.M. The data were 
analyzed by analysis of variance using post hoc analysis with the Fisher’s test. 
Probability values of <0.05 are considered to be statistically significant. 
 
Hypothesis 
Figure 1. Schematic representation of PKC activation generating SO release in PMN. PMN 
chemotactic G-protein receptors are activated by fMLP. The G-protein subunits q and βγ 
disassociate after stimulation and activate phospholipase C beta (PLCβ) and phosphatidyl inositol-
3-kinase gamma (PI-3kinγ) to produce inositol 1,4,5 trisphosphate (Ins(1,4,5)P2) plus DAG and 
PtdIns(3,4,5)P2 respectively from phospholipids phosphatidylinositol 4,5 bisphosphate 
(PtdIns(4,5)P2). Ins(1,4,5)P2 stimulates Ca
2+ release from the endoplasmic reticulum (ER). 
Ca2+/DAG and PtdIns(3,4,5)P2 directly activate PKC.  Activated PKC phosphorylates NADPH 
oxidase to release SO anion. Adapted  from Young et al. (2) 
 
SO release from leukocytes via NADPH oxidase activation contributes to 
oxidative stress under various diseases, such as ischemia/reperfusion (I/R) injury 
and vascular complications in diabetes.  NADPH oxidase has seven isoforms with 
NOX2 being the predominant isoform of NADPH oxidase in polymorphonuclear 
leukocytes (PMNs).  Activation of NOX2 requires the assembly of cytosolic 
subunits (p47phox, p40phox, p67phox, Rac) to membrane subunits (gp91 phox 
and p22phox) (1).  NADPH oxidase is activated during I/R injury via cytokine 
receptor stimulation or chemotactic factor (N-formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP, MW= 438 g/mol) and utilizes molecular oxygen to produce 
SO (2) (fig1). Gp91ds-tat is a peptide which selectivity inhibits NADPH oxidase 
assembly by blocking  p47phox interaction with gp91phox.  It is well known that 
adding myristic acid or tat carrier peptide to native peptides will facilitate cell 
membrane permeability required for targeting intracellular substrates. The addition 
of a glycine-glycine (GG) spacer between the tat and cargo portion of the peptide 
is reported to facilitate better delivery of the cargo sequence (i.e., CSTRIRRQL) 
(3,4). We have previously shown that myristic acid conjugated caveolin-1 and 
protein kinase C (PKC) beta II and zeta peptide inhibitors significantly attenuated 
fMLP-induced SO release compared to their native counterparts (5). However, it is 
not known if differences exist in the effectiveness of myristic acid versus tat 
conjugated gp91 ds-tat peptides compared to their native counterparts or untreated 
controls. 
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Figure 3. a- gp91ds-tat sequence (MW= 2452 g/mol). b- native gp91ds (MW=1131 g/mol). c-gg 
spacer (MW=2566 g/mol)  d- myristoylated (Myr-peg linker) (MW=1486 g/mol). Adapted from 
Rey et al. (3)  
Figure 2. Schematic showing the inactive and active forms of NADPH oxidase. Green-lines 
denote areas of inhibition performed by gp91ds-tat. Adapted from Wilkinson et al. (1)  
Figure 4. fMLP (1μM)-induced peak response SO release in PMNs.  Myr-peg gp91 (5 & 10 μM) significantly 
attenuated untreated (*p<0.01) and native gp91 (# p<0.05) induced SO release by 56-57 ± 8%  and 52-54 ± 9 % 
respectively.  Myr-peg gp91 (2 µM), gp91dstat (80 µM), and gg spacer (80 µM) significantly inhibited untreated by  
36 ± 11 % compared to untreated controls (*p<.05) and was not different from native gp91.  Concentrations of tat 
conjugated peptides ≤40 µM did not exert significant inhibition of PMN SO release. (data not shown) 
Figure 5. The time course response of fMLP (1μM)-induced SO release.  Myr-peg gp91 (5 & 10 μM) significantly 
inhibited untreated (**p<0.01, *p<0.05) and native gp91 (# p<0.05) by 44-56% and 46-52% respectively from 30-
120 sec. Myr-peg gp91 (2 µM), gp91dstat (80 µM), and gg spacer (80 µM) significantly untreated (*p<0.05) by 33-
36%  from 30-120 sec and was only different from native gp91 at 30 sec (#p<0.05). 
Figure 6. The effects of native, tat, and myristoylated conjugated gp91 on cell viability in fMLP (1 μM)-induced SO 
release in PMNs.  Cell viability ranged between 90-93% ± 1 and was not different amongst study groups indicating 
that the reduction in SO release were not related to cell death. 
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